Deep Genomics will use the money to advance drug candidates created through its AI drug development model, based on research by Toronto faculty.
Deep Genomics, a Canada-based genetic medicine developer based on research at University of Toronto, has completed a $40m series B round led by venture capital firm Future Ventures.
Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures also participated in the round, which boosted the company’s overall funding to nearly $57m.
Deep Genomics uses artificial intelligence-focused model to develop treatments for diseases with high unmet need, utilising AI in a range of areas including the identification of drug…
